Latest Breaking News On - Globenewswire inc - Page 8 : comparemela.com

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesJian zhangDominic smethurstBruce mackleYuval cohenSean moranCorbus pharmaceuticalsCorbus pharmaceuticals holdings incPharmaceuticals groupFudan university shanghai cancer centerAmerican society of clinical oncologyLifesci advisorsSecurities exchangeGlobenewswire incExchange commissionPharmaceuticals holdings

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic.

United statesAsia pacificAndrew carlsenFosun pharmaDavid freundelJudith klimovskyGlobenewswire incAmerican cancer societyAmerican society of clinical oncologyExchange commissionRoche groupClinical oncologyAnnual meetingExecutive vice presidentChief development officerChief medical officer

Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment .

United statesUnited kingdomBlack diamondNader sanaiPatrick wenMario corsoIvy brain tumor centerInternational conference on molecularGlobenewswire incExchange commissionAmerican society of clinical oncologyDiamond therapeutics incDana farber cancer instituteCompany masterkeyDiamond therapeuticsClinical oncology

Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort

In 17 EGFR wild-type non-small cell lung cancer patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved 4 objective responses; 3 of 4 responses were ongoing for more than 7.

Soult ukpyolsiSouth koreaUnited statesBaden wübergArtiva alloAlexander fudukidisMary beth sandinAndreas harstrickHye ryun kimYonsei university college of medicineUniversity of texas md anderson cancer centerGlobenewswire incChief medicalChief executive officerGryun kimUniversity college

Petrus Announces Results of Annual General Meeting of Shareholders

CALGARY, Alberta, May 30, 2024 Petrus Resources Ltd. is pleased to announce that its shareholders approved all resolutions at its annual general meeting of shareholders held May 29, 2024 . The.

Donald cormackKen grayPatrick arnellPeter verburgDonald grayPetrus resources ltdGlobenewswire incChartered professional accountantsChief executive